Navigation Links
Phase 3 Topical Drug for Raynaud's Disease Available for Licensing/Acquisition at the J.P. Morgan Conference
Date:12/13/2012

tary topical delivery system in late-stage clinical trials targeting infectious and inflammatory skin diseases and conditions. The Company's major efforts have been focused on projects targeting Raynaud's phenomenon, nail psoriasis and actinic keratosis. In addition to historical facts or statements of current condition, this press release contains forward-looking statements within the meaning of the 'Safe Harbor' provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements provide the Company's current expectation or forecasts of future events. MediQuest's performance and financial results could differ materially from those reflected in these forward-looking statements due to the decisions of regulatory authorities, ability to implement its commercial plans, general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industries generally. For a discussion of these and other risks and uncertainties that may affect the forward-looking statements please contact the Company. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. MediQuest undertakes no obligation to update publicly any forward-looking statement
www.mqti.com

Contact information
Joseph K. Piper
Managing Director, Point B Capital
jpiper@pointbcap.com
206-577-7223

Media Contact: Siavash Forootan MediQuest Therapeutics, 215-238-8881, sforootan@numodacapital.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE MediQuest Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Lilly Discontinues One of Three Phase 3 Rheumatoid Arthritis Registration Studies for Tabalumab
2. AstraZeneca Announces Top-Line Results of OSKIRA-4 Phase IIb Study of Fostamatinib as a Monotherapy for Rheumatoid Arthritis
3. Insero Health Completes Phase I Trial of Novel Therapy in Patients With Drug Resistant Epilepsy
4. Unigenes Phase 2 Study of Oral PTH for the Treatment of Osteoporosis in Postmenopausal Women Featured in Bone
5. Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, in Relapsed/Refractory Mantle Cell Lymphoma Presented at American Society of Hematology Annual Meeting
6. Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, Suggest High and Durable Responses in Relapsed/Refractory Mantle Cell Lymphoma
7. uniQure Initiates Phase I in Acute Intermittent Porphyria
8. Ambit and Astellas Announce Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the 54th Annual Meeting of the American Society of Hematology
9. Boehringer Ingelheim Presents New Phase II Data for Volasertib in Adult Patients with AML
10. Spinifex Announces Start of Phase 2 Proof-of-Concept Trial of EMA401 in Chemotherapy-Induced Peripheral Neuropathy
11. Phase II Trial of Sanofi JAK2 Inhibitor in Myelofibrosis Met Primary Endpoint
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Jan. 15, 2014 Massachusetts General Hospital (MGH), ... AMGN ) announced today that they have launched ... new therapeutic targets and develop novel therapies for ... affects millions worldwide. The MGH-Broad-Amgen collaboration brings together ...
(Date:1/15/2014)... , Jan. 15, 2014  Humberto C. Antunes,  Galderma  ... Award" from the Journal of Drugs in Dermatology ... Clinical Conference (ODAC). The event is January 17-20, 2014, at the ... . The ODAC is a ...
(Date:1/15/2014)... Ky. , Jan. 15, 2014  Manufacturers, suppliers ... must be able to protect their most important ... http://photos.prnewswire.com/prnh/20130716/CL46586LOGO ) Because of ... it steadfastly remains one of the most litigious ...
Breaking Medicine Technology:Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4Intellectual Property Insurance for Medical-related Products and Services 2
... 2011 Seal Shield LLC today announced ... for the iPad.  The product has been designed specifically ... use in hospital settings. The Seal Shield ... which is resistant to liquids including blood and bleach. ...
... MALVERN, Pa., Feb. 21, 2011 Today, Siemens (NYSE: ... Overhage, MD, PhD, as Chief Medical Informatics Officer (CMIO), of ... of the In diana Health Information Exchange ... this not-for-profit organization. In his role at Siemens, Marc will ...
Cached Medicine Technology:Siemens Appoints Overhage as New Chief Medical Informatics Officer 2
(Date:4/17/2014)... recent papers by a University of Colorado School ... develop treatments or vaccines for Dengue fever, West ... disease-causing flaviviruses. , Jeffrey S. Kieft, PhD, associate ... School of Medicine and an early career scientist ... recently published articles in the scholarly journals ...
(Date:4/17/2014)... April 17, 2014U.S. military personnel who served in ... concussive traumatic brain injury (TBI) were compared to ... other medical reasons. Differences in measures of overall ... months after injury are reported in an article ... journal from Mary Ann Liebert, Inc., publishers. The ...
(Date:4/17/2014)... 17, 2014-- Colic affects about one in five infants ... pediatric visits during the first several months after birth. ... was showing promise; however, the April 1, 2014 issue ... Valerie) reported on a study, "Probiotics and Infant Colic," ... reuteri for infant colic did not reduce ...
(Date:4/17/2014)... by researchers at UC Davis has shown that the ... in cell division, also boosts the mitochondrial activity to ... complex has been shown to perform both jobs. This ... to control cellular energy production, potentially advancing cancer care ... in the journal Developmental Cell . , "These ...
(Date:4/17/2014)... colored ribbon representing a disease. A pink ribbon is well ... one think of with lung cancer?, Although white has been ... disease, black may be the only one they think fits., ... primarily smokers between the ages of 51 to 79 years ... by these patients, the emotional toll it can have and ...
Breaking Medicine News(10 mins):Health News:CU researchers discover target for treating dengue fever 2Health News:Long-term effects of battle-related 'blast plus impact' concussive TBI in US military 2Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2Health News:Dual role: Key cell division proteins also power up mitochondria 2Health News:Unraveling the 'black ribbon' around lung cancer 2
... $25 million project to reduce throughout the beef production chain ... a major threat to public health. The U.S. Department ... grant at UNL on Monday, Jan. 23. The project ... cause more than 265,000 illnesses in the United States annually. ...
... Higher than normal levels of lead in the blood may ... renal cell carcinoma in smokers, according to medical researchers. ... kidneys from individuals without cancer, kidneys from individuals with cancer ... at Penn State College of Medicine. "But prior to this ...
... HealthDay Reporter , SUNDAY, Jan. 22 (HealthDay ... they believe are linked with breast cancer that may ... All three newly identified areas "contain interesting genes that ... said researcher Douglas Easton, a professor of genetic epidemiology ...
... Angry Men," Henry Fonda,s character sways a jury with his ... had allowed himself to fall sway to the social dynamics ... Virginia Tech Carilion Research Institute found that small-group dynamics -- ... -- can alter the expression of IQ in some susceptible ...
... yoga in a room heated to between 90 and 105 degrees ... it may not be for everyone, an expert warns. Exertion ... conditions, said Diana Zotos, a yoga instructor and physical therapist ... New York City. "If you have sensitivity to ...
... -- Monkeys vaccinated with an anthrax capsule vaccine were protected ... The anthrax capsule is a naturally occurring component of ... is the first successful use of a non-toxin vaccine to ... the most serious bioterrorism threats, according to the U.S. Army ...
Cached Medicine News:Health News:U. of Nebraska to lead $25 million project targeting E. coli threat 2Health News:U. of Nebraska to lead $25 million project targeting E. coli threat 3Health News:Lead blood levels may increase smokers' risk for kidney cancer 2Health News:Lead blood levels may increase smokers' risk for kidney cancer 3Health News:New Genetic Clues to Breast Cancer? 2Health News:New Genetic Clues to Breast Cancer? 3Health News:Group settings can diminish expressions of intelligence, especially among women 2Health News:Group settings can diminish expressions of intelligence, especially among women 3Health News:Avoid Getting Scorched by 'Hot Yoga' 2Health News:Anthrax Vaccine Shows Promise in Monkeys 2
For use under silicone strips E5381 610, E5381 611 and E5381 710. Indications: When higher buckle is required. Overall length: 6.1 mm....
Ungrooved permanent silicone strip. Indications: For trapdoor procedure. Overall length: 125 mm, 4.9 inches....
Used with Double Tantalum Clip (250 style) E5381 852. Overall length: 7.0 mm....
Our largest silicone tire with concave inner surface. Used in conjunction with the E5381 700 Circling Band (240 style). Indications: Massive breaks covering large areas. Outside diameter 31.7 mm....
Medicine Products: